Overview

Study Evaluating PK/PD and Safety of Betrixaban in Pediatric Patients

Status:
Completed
Trial end date:
2019-10-08
Target enrollment:
Participant gender:
Summary
A Phase 1, Open-Label, Single-Dose, Non-Randomized Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of Betrixaban in Pediatric Patients
Phase:
Phase 1
Details
Lead Sponsor:
Portola Pharmaceuticals
Treatments:
Betrixaban